Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Use of secondary stroke prevention medicines in Australia: national trends, 2003-2009

- Featured Image

Individuals diagnosed with transient ischaemic attack (TIA) or ischaemic stroke are at high risk of recurrent vascular events.1,2 Current Australian guidelines recommend continued use of antihypertensive, antithrombotic and lipid-lowering medicines after TIA or ischaemic stroke to reduce the risk of a recurrent ischaemic event, unless contraindications exist.3

In Australia, a national audit is conducted every 2 years to assess the quality of acute stroke care, including use of secondary stroke prevention medicines at the time of hospital discharge.4 However, few studies have examined use of secondary stroke prevention medicines after discharge from hospital.5,6 Of those available, none have assessed changes in use of these medicines at the national level, and it is unclear whether use has increased since the release of Australia’s first stroke management guidelines in 2003. Consequently, the aim of this study was to examine national trends in the use of secondary stroke prevention medicines by TIA and ischaemic stroke survivors to determine whether use has increased over time.


A retrospective observational study was conducted using data from the Australian Government Department…